Paladin Phase 4 study confirms fluocinolone acetonide intravitreal implant patients' reduced need for multiple treatments
Visiox Pharma submits NDA seeking approval for first once-daily brimonidine for glaucoma
EP. 3: EyeCon 2022: High-impact content in a small-scale setting
